The results showed 1.5 (p = 0.016) and 2.5 (p ≤0.001) fold increase of serum acyl-Ghr levels in patients with NAFLD and normal or elevated transaminases compared with control groups (OR 1.791; 95% CI 1.162 – 2.759; p = 0.008). This evidence concerns the gene GHR and metabolic dysfunction-associated steatotic liver disease.